

# CANCER CONSORTIUM AWARDS \$1.34M IN RESEARCH DEVELOPMENT PROJECTS



## 2019 AWARD RECIPIENTS



Each year, through a highly competitive process, the Fred Hutch/University of Washington Cancer Consortium awards research grants to fuel new scientific pursuits and interdisciplinary collaborations. Awards provide up to \$80,000 in direct costs and support innovative proposals which are reviewed by Consortium experts and leaders. This year, a special focus has been placed on projects targeting cross-disciplinary research in health disparities (\*), catchment area needs (‡), and early career scientists (^). More than \$1.34M in cancer-focused research funding has been awarded to 15 Consortium faculty since April 2019.

### 2019 Pilot Grant Awardees

Fred Hutch

**Rachel Ceballos, PhD** \* (Cancer Epidemiology, Prevention & Control): *Adaptation and evaluation of an in-person and eHealth diet and physical activity program for rural Latino cancer survivors*

**Eric Chow, MD, MPH ‡** (Hematologic Malignancies): *Improving cancer survivorship care delivery: telehealth & lay health educators*

University of Washington

**Shreeram Akilesh, MD, PhD ^** (Cancer Basic Biology): *T cell mediated killing of kidney cancer in a microphysiological system*

## 2019 Safeway Pilot Grant Awardees

Fred Hutch

**Taran Gujral, PhD ^** (GI Cancer/Prostate Cancer): *Wnt signaling pathway in anti-tumor immunity*

**Salene Jones, PhD ^** (Cancer, Epidemiology, Prevention & Control): *Pilot of precision patient-reported outcomes for clinical trials and clinical care*

**John Lee, MD, PhD ^** (Prostate Cancer): *Targeting prostate cancer with STEAP1 chimeric antigen receptor T cell therapy*

**Parth Shah, ParmD, PhD \* ^** (Cancer, Epidemiology, Prevention & Control): *The role of community pharmacy in colorectal cancer screening*

University of Washington

**Anna Halpern, MD ^** (Hematologic Malignancies): *A Phase 2 trial investigating decitabine in combination with Ruxolitinib as a bridge to allogeneic hematopoietic stem cell transplant in patients with accelerated phase myeloproliferative neoplasms*

**Scott Kennedy, PhD ^** (Cancer Basic Biology): *Accumulation of age-associated cancer-like mutations in normal tissues and the effects of aging interventions*

**Kathryn Lowry, MD ^** (Cancer, Epidemiology, Prevention & Control): *Utilization of decision analysis to inform design of a clinical trial for management of high-risk breast lesions*

**David Shechner, PhD ^** (Cancer Basic Biology): *Dissecting the RNA structures that drive nucleolar assembly as novel chemotherapeutic targets*

## 2019 New Investigator Awardees

Fred Hutch

**Susan Bullman, PhD ^** (Pathogen Associated Malignancies): *Genomic and functional analysis of intra-tumoral microbiota in colorectal cancer: moving from correlation to causation*

**Gavin Ha, PhD ^** (Biostatistics & Computational Biology): *Characterizing molecular signatures in advanced prostate cancer using liquid biopsies*

Seattle Children's

**Heather Gustafson, PhD ^** (Cancer Immunology): *Innate immune transcriptional regulation as a predictor of patient-specific safety in CAR-T immunotherapy*

University of Washington

**Teresa Kim, MD** ^ (Other Oncology Research): Activating tumor-associated macrophages through blockade of interleukin-10

The Cancer Consortium's mission is to eliminate cancer through more effective prevention, diagnostics and treatment, and fundamental insights into the biology of the disease. In a time where NIH funding is dwindling, the Cancer Consortium, via the NCI Cancer Center Support Grant (P30 CA015704), provides an important mechanism to stimulate innovative, first-in-kind research that will launch next-generation discoveries.

Congratulations to all of this year's award recipients!